Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences Inc., filed a Form 4 on August 26, 2026, reporting three sales of common stock held indirectly through the Fritz Shorter Trust on August 24 and August 25, 2026.

Key Highlights

  • Three sales reported: 12,218 shares sold on 08/24/2026 and two separate lots of 7,161 and 5,223 shares sold on 08/25/2026, all coded as "S" (open-market sale).
  • Weighted-average prices: $33.687 per share on 08/24/2026; $34.263 per share for the first 08/25/2026 transaction; and $34.639 per share for the second 08/25/2026 transaction.
  • Total shares disposed: 24,602 shares across the three transactions, all held indirectly.
  • Remaining indirect holdings: 72,649 shares held indirectly through the Fritz Shorter Trust following the final reported transaction.
  • Direct holdings: 13,288 shares held directly by the reporting person, as disclosed in Table I.
  • Trust structure: Shares are held by the Fritz Shorter Trust, of which the reporting person and her spouse are both trustees and beneficiaries, according to the filing.

Oelschlager's Share Sales: Transaction Details and Beneficial Ownership

According to the filing, Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences Inc. (NASDAQ:CSTL), disposed of common stock on two consecutive trading days. On August 24, 2026, she sold 12,218 shares at a weighted-average price of $33.687, with individual trade prices ranging from $33.500 to $33.885, inclusive. Following that transaction, the Fritz Shorter Trust held 85,033 shares indirectly.

On August 25, 2026, two additional sales were reported. The first involved 7,161 shares at a weighted-average price of $34.263, with individual trades ranging from $33.470 to $34.460, inclusive, reducing indirect holdings to 77,872 shares. The second sale on the same date covered 5,223 shares at a weighted-average price of $34.639, with individual trades ranging from $34.495 to $34.750, inclusive, bringing indirect holdings to 72,649 shares. All three transactions carried transaction code "S" and are held through the Fritz Shorter Trust, in which the reporting person and her spouse serve as trustees and beneficiaries.

The filing also discloses that Oelschlager holds 13,288 shares directly. The Form 4 was signed by Frank Stokes as attorney-in-fact on August 26, 2026. The filing notes that each weighted-average price reflects multiple individual trades, and the reporting person undertakes to provide full detail on individual trade prices upon request by the SEC staff, the issuer, or a security holder.

What Was Disclosed

The Form 4 discloses three open-market sales of Castle Biosciences common stock by COO Kristen M. Oelschlager, totaling 24,602 shares sold indirectly through the Fritz Shorter Trust on August 24-25, 2026, with 72,649 indirect shares and 13,288 direct shares remaining afterward.